Promising drug cocktail aims to control aggressive breast cancer

NCT ID NCT06690840

Recruiting now Disease control Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs (atezolizumab, vinorelbine, and cyclophosphamide) in people with advanced triple-negative breast cancer that has spread. Participants have already received immunotherapy before. The goal is to see if this new mix can shrink tumors or slow the disease. About 45 people will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Azienda Sanitaria Locale Br
NOT_YET_RECRUITING

Brindisi, Italy
European Institute of Oncology
RECRUITING

Milan, 20141, Italy
Fondazione IRCCS San Gerardo Dei Tintori
RECRUITING

Monza, Monza, 20900, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NOT_YET_RECRUITING

Roma, Roma, 00168, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NOT_YET_RECRUITING

Roma, Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.